One of Europe’s most cheaply valued drugmakers, the £75 bln group run by Luke Miels is turning a corner. Fears over expiring patents are easing thanks to a booming oncology unit. A £40 bln sales target looks hard, but Miels may fix that with canny dealmaking and luck in the lab.
Log in or sign up to comment.